Method for preparing pyrrolo[3,2,-d]pyrimidine compound, and intermediates thereof
US-2020239484-A1 · Jul 30, 2020 · US
Compounds, compositions and methods
US12358928B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12358928-B2 |
| Application number | US-202318232435-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 10, 2023 |
| Priority date | Feb 5, 2016 |
| Publication date | Jul 15, 2025 |
| Grant date | Jul 15, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof, that is chosen from: No. Structure 38A 38B 200 2. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof of claim 1 , and a pharmaceutically acceptable excipient. 3. A compound having the structure: or a tautomer, stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 5. The compound according to claim 1 , having the structure: or a tautomer, stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. 6. A pharmaceutical composition comprising a compound of claim 5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 7. The compound according to claim 1 , compound having the structure: or a tautomer, stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition comprising a compound of claim 7 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
- C07D495/04Primary
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12358928B2 cover?
- The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
- Who is the assignee on this patent?
- Denali Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).